Excellent therapeutic options are Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and the new GLP1 and gastric inhibitory polypeptide dual receptor antagonists counteract metabolic defects of type 2 diabetes, hyperglycemia and obesity. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.